post-traumatic stress disorder – Page 3

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids

mycolabadmin

Scientists analyzed 226 mushroom samples from about 30 psychotropic species to measure their psilocybin and related compound content. They found that the amounts of these compounds vary greatly, even within the same species, making it difficult to predict how strong a mushroom will be. The research shows that Psilocybe species generally contain the most psychoactive compounds, with some varieties containing over 15 times more psilocybin than others, highlighting safety concerns for users.

Global species diversity and distribution of the psychedelic fungal genus Panaeolus

mycolabadmin

This study is a comprehensive catalog of 77 Panaeolus mushroom species worldwide, of which 20 are known to be hallucinogenic and contain psilocybin. Researchers found that these mushrooms are most commonly documented in Asia, South America, and Europe, but many regions have little to no research data. The review highlights significant gaps in our knowledge about where these species exist and which ones truly contain psychoactive compounds, information that is crucial as these fungi become legal in more countries for medical use.

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study

mycolabadmin

This study examines how antidepressant medications (like SSRIs) affect the experience of classic psychedelics such as psilocybin and LSD. Researchers found that people taking these antidepressants experienced less intense emotional and mystical effects from psychedelics, but surprisingly, both groups showed similar improvements in mood and well-being several weeks later. This raises important questions about whether patients need to stop their antidepressants before using psychedelics therapeutically.

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review

mycolabadmin

This review examines how psilocybin, a compound found in certain mushrooms, may help people recover from traumatic brain injuries. The research suggests that psilocybin could reduce harmful inflammation in the brain, help the brain form new connections to compensate for damage, and improve mood and depression commonly experienced after brain injuries. While promising, the authors emphasize that more clinical trials are needed to confirm safety and effectiveness before psilocybin can be used to treat brain injury patients.

Toxicology and Analysis of Psychoactive Tryptamines

mycolabadmin

Tryptamines are a growing class of psychoactive drugs that can cause hallucinations and other dramatic changes in perception. These substances, including compounds like DMT and psilocybin from magic mushrooms, work by affecting serotonin receptors in the brain. While some research explores their potential medical use for treating depression and anxiety, they also carry serious risks including dangerous changes in heart rate, body temperature, and mental state. Scientists have developed new laboratory methods to detect these drugs in blood and urine samples to help doctors diagnose and treat overdoses.

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia

mycolabadmin

Australia has recently approved psilocybin and MDMA for treating severe depression and PTSD when used with professional therapy support. This paper creates a comprehensive guide outlining all the regulatory, professional, and safety considerations needed to safely deliver these treatments in clinical settings. The researchers interviewed 11 experts and reviewed existing research to identify 102 specific matters that need clear guidelines, such as what qualifications therapists need, where treatments can be delivered, how patients should be screened, and what safety measures are essential.

The development of psilocybin therapy for treatment-resistant depression: an update

mycolabadmin

Psilocybin, a compound found in certain mushrooms, is being studied as a potential treatment for severe depression that doesn’t respond to standard medications. In clinical trials, patients receiving psilocybin alongside psychological support showed significant improvement in depressive symptoms within days to weeks, with benefits lasting for months. Unlike daily antidepressant pills, psilocybin therapy involves one or more carefully supervised dosing sessions in a hospital setting with therapeutic support before and after. Larger studies are underway to confirm its effectiveness and safety before it could potentially become an approved treatment.

Three New Fungi from China: A Potentially Psychoactive Psilocybe and Two Deconica Species

mycolabadmin

This research describes three new mushroom species from China: Psilocybe striata and two Deconica species. Psilocybe striata is notable for its blue bruising and potential psychoactive properties, expanding where we know psilocybin mushrooms grow. The study used both physical characteristics and genetic analysis to identify and classify these fungi, discovering that China has much greater fungal diversity than previously documented.

Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study

mycolabadmin

This study examined how childhood trauma can resurface during psychedelic experiences and what happens afterward. Researchers surveyed over 600 people who had difficult experiences after using psychedelics, and interviewed 18 of them in detail. They found that trauma surfaced in different ways—some people vividly relived events, others felt intense bodily sensations, and some experienced confusion. About half of participants found healing from the experience, while others struggled with ongoing trauma symptoms or mixed outcomes. The research emphasizes the importance of proper preparation, supportive settings, and follow-up integration work to help people process these experiences safely.

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

mycolabadmin

This Australian study surveyed over 500 people about their views on psychedelics like psilocybin and MDMA for treating mental health conditions. Most people supported medical legalization of these substances, though many had safety concerns. Those with mental illness, those with prior psychedelic experience, and those with better knowledge of psychedelics were most supportive of their therapeutic use.

Disease: post-traumatic stress disorder